AMH mutations with reduced in vitro bioactivity are related to premature ovarian insufficiency

Human Reproduction

Volumn 30, Issue 5, 2015, Pages 1196-1202

  Alvaro Mercadal, B ^a,b   Imbert, R ^b   Demeestere, I ^a,b   Gervy, C ^b   De Leener, A ^b   Englert, Y ^a,b   Costagliola, S ^a   Delbaere, A ^a,b  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b ERASME HOSPITAL   (Belgium)

Author keywords

AMH; AMH bioactivity; AMH mutations; POI; premature ovarian insufficiency

Indexed keywords

COMPLEMENTARY DNA; FOLLITROPIN; GENOMIC DNA; MUELLERIAN INHIBITING FACTOR; DNA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE MUTATION; HEK293 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; MISSENSE MUTATION; OVARY FOLLICLE; POLYMERASE CHAIN REACTION; PREMATURE OVARIAN FAILURE; WESTERN BLOTTING; ADOLESCENT; AMENORRHEA; ANIMAL; COHORT ANALYSIS; EXON; GENETIC VARIABILITY; GENETICS; INTRON; MOUSE; MUTATION; NUCLEOTIDE SEQUENCE; OVARY; PHYSIOLOGY; YOUNG ADULT;

MUS;

ADOLESCENT; ADULT; AMENORRHEA; ANIMALS; ANTI-MULLERIAN HORMONE; COHORT STUDIES; DNA; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; GENETIC VARIATION; HEK293 CELLS; HUMANS; INTRONS; MICE; MUTATION; MUTATION, MISSENSE; OVARY; PRIMARY OVARIAN INSUFFICIENCY; YOUNG ADULT;

EID: 84929756239     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/dev042     Document Type: Article

References (32)

1. Anderson RA, Nelson SM, Wallace WHB. Measuring anti-Mullerian hormone for the assessment of ovarian reserve: when and for whom is it indicated?. Maturitas 2012;71:28-33.
2. Braem MGM, Voorhuis M, van der Schouw YT, Peeters PHM, Schouten LJ, Eijkemans MJC, Broekmans FJ, Onland-Moret NC. Interactions between genetic variants in AMH and AMHR2 may modify age at natural menopause. PLoS one 2013;8:e59819.
3. Broer SL, Broekmans FJM, Laven JSE, Fauser BCJM. Anti-Mullerian hormone: ovarian reserve testing and its potential clinical implications. Hum Reprod Update 2014;20:688-701.
4. Christin-Maitre S, Braham R. General mechanisms of premature ovarian failure and clinical check-up. Gynecol Obstet Fertil 2008;36:857-861.
5. De Vet A, Laven JS, de Jong FH, Themmen AP, Fauser BC. Antimullerian hormone serum levels: a putative marker for ovarian aging. Fertil Steril 2002;77:357-362.
6. Di Pasquale E, Rossetti R, Marozzi A, Bodega B, Borgato S, Cavallo L, Einaudi S, Radetti G, Russo G, Sacco M et al. Identification of new variants of human BMP15 gene in a large cohort of women with premature ovarian failure. J Clin Endocrinol Metab 2006;91:1976-1979.
7. Dixit H, Rao LK, Padmalatha VV, Kanakavalli M, Deenadayal M, Gupta N, Chakrabarty B, Singh L. Missense mutations in the BMP15 gene are associated with ovarian failure. Hum Genet 2006;119:408-415.
8. Durlinger AL, Kramer P, Karels B, de Jong FH, Uilenbroek JT, Grootegoed JA, Themmen AP. Control of primordial follicle recruitment by anti-Mullerian hormone in the mouse ovary. Endocrinology 1999;140:5789-5796.
9. Josso N, Clemente ND. Transduction pathway of anti-Mullerian hormone, a sex-specific member of the TGF-b family. Trends Endocrinol Metab 2003; 14:91-97.
10. Josso N, Rey R, Picard J-Y. Testicular anti-Mullerian hormone: clinical applications in DSD. Semin Reprod Med 2012;30:364-373.
11. Jost A. Surlero le des gonades dans la differentiation sexuelle somatique de l'embryon de lapin. C R Assoc Anat 1947;34:255-263.
12. Kananen K, Markkula M, Rainio E, Su JG, Hsueh AJ, Huhtaniemi IT. Gonadal tumorigenesis in transgenic mice bearing the mouse inhibin alpha-subunit promoter/simian virus T-Antigen fusion gene: characterization of ovarian tumors and establishment of gonadotropin-responsive granulosa cell lines. Mol Endocrinol 1995;9:616-627.
13. Kevenaar ME, Laven JSE, Fong SL, Uitterlinden AG, de Jong FH, Themmen APN, Visser JA. A functional anti-Mullerian hormone gene polymorphism is associated with follicle number and androgen levels in polycystic ovary syndrome patients. J Clin Endocrinol Metab 2008; 93:1310-1316.
14. Knight PG, Glister C. TGF-superfamily members and ovarian follicle development. Reproduction 2006;132:191-206.
15. Kumar P, Henikoff S, NgPC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 2009; 4:1073-1081.
16. Laissue P, Christin-Maitre S, Touraine P, Kuttenn F, Ritvos O, Aittomaki K, Bourcigaux N, Jacquesson L, Bouchard P, Frydman R et al. Mutations and sequence variants in GDF9 and BMP15 in patients with premature ovarian failure. Eur J Endocrinol 2006;154:739-744.
17. Matsuda F, Inoue N, Manabe N, Ohkura S. Follicular growth and atresia in mammalian ovaries: regulation by survival and death of granulosa cells. J Reprod Dev 2012;58:44-50.
18. MatzukMM, Lamb DJ. The biology of infertility: research advances and clinical challenges. Nat Med 2008;14:1197-1213.
19. Nelson LM. Primary ovarian insufficiency. N Engl J Med 2009;360:606-614.
20. Otsuka F, McTavish KJ, Shimasaki S. Integral role of GDF-9 and BMP-15 in ovarian function. Mol Reprod Dev 2011;78:9-21.
21. Pepinsky RB, Sinclair LK, Chow EP, Mattaliano RJ, Manganaro TF, Donahoe PK, Cate RL. Proteolytic processing of Mullerian inhibiting substance produces a transforming growth factor-beta-like fragment. J Biol Chem 1988;263:18961-18964.
22. Persani L, Rossetti R, Cacciatore C. Genes involved in human premature ovarian failure. J Mol Endocrinol 2010;45:257-279.
23. Qin C, Yuan Z, Yao J, Zhu W, Wu W, Xie J. AMH and AMHR2 genetic variants in Chinese women with primary ovarian insufficiency and normal age at natural menopause. Reprod Biomed Online 2014;29: 311-318.
24. Rajpert-De Meyts E, Jorgensen N, Graem N, Muller J, Cate RL, Skakkebaek NE. Expression of anti-Mullerian hormone during normal and pathological gonadal development: association with differentiation of Sertoli and granulosa cells. J Clin Endocrinol Metab 1999;84:3836-3844.
25. Sunyaev S, Lathe W, Bork P. Integration of genome data and protein structures: prediction of protein folds, protein interactions and molecular phenotypes of single nucleotide polymorphisms. Curr Opin Struct Biol 2001;11:125-130.
26. Tiotiu D, Alvaro Mercadal B, Imbert R, Verbist J, Demeestere I, De Leener A, Englert Y, Vassart G, Costagliola S, Delbaere A. Variants of the BMP15 gene in a cohort of patients with premature ovarian failure. Hum Reprod 2010;25:1581-1587.
27. Van Kasteren YM, Hundscheid RD, Smits AP, Cremers FP, van Zonneveld P, Braat DD. Familial idiopathic premature ovarian failure: an overrated and underestimated genetic disease?. Hum Reprod 1999;14:2455-2459.
28. Visser JA, Themmen APN. Role of anti-Mu llerian hormone and bone morphogenetic proteins in the regulation of FSH sensitivity. Mol Cell Endocrinol 2014;382:460-465.
29. Visser JA, Durlinger ALL, Peters IJJ, van den Heuvel ER, Rose UM, Kramer P, de Jong FH, Themmen APN. Increased oocyte degeneration and follicular atresia during the estrous cycle in anti-Mullerian hormone null mice. Endocrinology 2007;148:2301-2308.
30. Weenen C, Laven JSE, Bergh Von ARM, Cranfield M, Groome NP, Visser JA, Kramer P, Fauser BCJM, Themmen APN. Anti-Mullerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod 2004;10:77-83.
31. Wilson CA, di Clemente N, Ehrenfels C, Pepinsky RB, Josso N, Vigier B, Cate RL. Mullerian inhibiting substance requires its N-Terminal domain for maintenance of biological activity, a novel finding within the transforming growth factor-beta superfamily. Mol Endocrinol 1993; 7:247-257.
32. Yoon SH, Choi YM, Hong MA, Kim JJ, Lee GH, Hwang KR, Moon SY. Association study of anti-Mullerian hormone and anti-Mullerian hormone type II receptor polymorphisms with idiopathic primary ovarian insufficiency. Hum Reprod 2013;28:3301-3305.